Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Lean intervention improves patient discharge times, improves emergency department throughput and reduces congestion.

Beck MJ, Okerblom D, Kumar A, Bandyopadhyay S, Scalzi LV.

Hosp Pract (1995). 2016 Dec;44(5):252-259. Epub 2016 Nov 15.

PMID:
27791449
2.

An assessment of variables affecting transition readiness in pediatric rheumatology patients.

Bingham CA, Scalzi L, Groh B, Boehmer S, Banks S.

Pediatr Rheumatol Online J. 2015 Oct 13;13(1):42. doi: 10.1186/s12969-015-0040-x.

3.

Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature.

Gurion R, Tangpricha V, Yow E, Schanberg LE, McComsey GA, Robinson AB; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators..

Pediatr Rheumatol Online J. 2015 Apr 23;13:13. doi: 10.1186/s12969-015-0008-x. Review.

4.

Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy.

Robinson AB, Tangpricha V, Yow E, Gurion R, Schanberg LE, McComsey GA; APPLE Investigators..

Lupus Sci Med. 2014 Sep 10;1(1):e000037. doi: 10.1136/lupus-2014-000037. eCollection 2014 Sep 10.

5.

Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy.

Robinson AB, Tangpricha V, Yow E, Gurion R, McComsey GA, Schanberg LE; APPLE Investigators..

Lupus Sci Med. 2014 Apr 30;1(1):e000011. doi: 10.1136/lupus-2014-000011. eCollection 2014 Apr 30.

6.

Patient preferences and satisfaction in a multispecialty infusion center.

Ostrov BE, Reynolds K, Scalzi LV.

Patient Prefer Adherence. 2014 May 19;8:755-61. doi: 10.2147/PPA.S63214. eCollection 2014 May 19.

7.

Peripheral vascular disease in systemic lupus patients.

June RR, Scalzi LV.

J Clin Rheumatol. 2013 Oct;19(7):367-72. doi: 10.1097/RHU.0000000000000017.

PMID:
24048099
8.

Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Wahezi DM, Ilowite NT, Wu XX, Pelkmans L, Laat B, Schanberg LE, Rand JH; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators..

Lupus. 2013 Jun;22(7):702-11. doi: 10.1177/0961203313490241. Epub 2013 May 20.

9.

Short-term perioperative all-cause mortality and cardiovascular events in women with systemic lupus erythematosus.

Yazdanyar A, Wasko MC, Scalzi LV, Kraemer KL, Ward MM.

Arthritis Care Res (Hoboken). 2013 Jun;65(6):986-91. doi: 10.1002/acr.21915.

10.

Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators..

Arthritis Rheum. 2012 Jan;64(1):285-96. doi: 10.1002/art.30645.

11.

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Ardoin SP, Schanberg LE, Sandborg C, Yow E, Barnhart HX, Mieszkalski Kl, Ilowite NT, von Scheven E, Eberhard A, Levy DM, Kimura Y, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung LK, Imundo L, Soep JB, Reed AM; APPLE investigators..

Lupus. 2010 Oct;19(11):1315-25. doi: 10.1177/0961203310373937.

12.
13.
14.

The relationship between race, cigarette smoking and carotid intimal medial thickness in systemic lupus erythematosus.

Scalzi LV, Bhatt S, Gilkeson RC, Shaffer ML.

Lupus. 2009 Dec;18(14):1289-97. doi: 10.1177/0961203309345781. Epub 2009 Oct 27.

15.

NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain.

Rosé CD, Aróstegui JI, Martin TM, Espada G, Scalzi L, Yagüe J, Rosenbaum JT, Modesto C, Cristina Arnal M, Merino R, García-Consuegra J, Carballo Silva MA, Wouters CH.

Arthritis Rheum. 2009 Jun;60(6):1797-803. doi: 10.1002/art.24533.

16.

Cardiovascular disease risk awareness in systemic lupus erythematosus patients.

Scalzi LV, Ballou SP, Park JY, Redline S, Kirchner HL.

Arthritis Rheum. 2008 May;58(5):1458-64. doi: 10.1002/art.23419.

17.

Nonclassic neurologic features in cryopyrin-associated periodic syndromes.

Ting TV, Scalzi LV, Hashkes PJ.

Pediatr Neurol. 2007 May;36(5):338-41.

PMID:
17509468
18.

Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.

Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, Genin A, Van Dyke AL, Nackos E, Chander A, Gehrie E, Cron RQ, Whitehead AS.

Arthritis Rheum. 2006 Jul;54(7):2220-7.

19.

Remittive agents in pediatric rheumatology.

Singer NG, Scalzi LV.

Curr Opin Rheumatol. 2004 Sep;16(5):571-6. Review.

PMID:
15314497
20.

Is there a role for Chlamydia pneumoniae infection in systemic lupus erythematosus and in the associated atherosclerotic cardiovascular disease?

Kitumnuaypong T, Scalzi LV, Nalbant S, Von Feldt JM, Schumacher HR Jr.

Clin Exp Rheumatol. 2004 May-Jun;22(3):339-42.

PMID:
15144130

Supplemental Content

Loading ...
Support Center